Drug Profile
Research programme: Pim kinase inhibitors - Theravalues
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Theravalues Corporation
- Class
- Mechanism of Action PIM3 protein inhibitors; Proto oncogene proteins c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
- 17 May 2012 Preclinical trials in Cancer in Japan (unspecified route)